Study Comparing Intraperitoneal Bupivacaine and Placebo for Pain Relief After Open Appendectomy in Adults

What this Trial Is About

Researchers are comparing the effects of intraperitoneal bupivacaine instillation versus a placebo as preemptive pain relief in patients undergoing open appendectomy. The study focuses on evaluating pain management outcomes after surgery, specifically looking at postoperative pain within 24 hours. This is a phase 1 trial involving adult patients aged 20 to 60 undergoing emergency open appendectomy. Participants are randomly assigned to receive either 0.25% bupivacaine or 10 ml of normal saline instilled into the peritoneal cavity at the end of the operation. Both groups will have surgery duration noted, and pain relief and analgesic use will be monitored at 2, 6, 12, and 24 hours postoperatively. Rescue medications like ketorolac and nalbuphine will be used if pain scores reach certain levels. All patients will receive intravenous paracetamol as first-line analgesia. Patients are expected to be discharged two days after surgery once diet and pain are manageable, with additional oral pain medications provided if needed. During the study, researchers will closely record analgesic consumption and pain scores using a visual analogue scale. Follow-up will continue according to protocol to monitor ongoing pain and recovery. All information will be collected on a standardized form. The main outcome measured is postoperative pain within the first 24 hours. The trial aims to determine whether bupivacaine instillation offers better pain control compared to placebo during open appendectomy procedures.

Comparison Of Clinical Outcomes of Intraperitoneal Bupivacaine Instillation Versus Placebo as Preemptive Analgesia in Patients Undergoing Open Appendectomy